A Study Combining the M3814 Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer Patients

Conditions:   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fallopian Tube Undifferentiated Carcinoma;   FIGO Grade 1 Endometrial Endometrioid Adenocarcinom a;   FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma;   FIGO Grade 3 Endometrial Endometrioid Adenocarcinoma;   High Grade Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Undifferentiated Carcinoma;   Platinum-Sensitive Ovarian Carcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Primary Peritoneal Transitional Cell Carcinoma;   Primary Peritoneal Undifferentiated Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Low Grade Fallopian Tube Serous Adeno carcinoma;   Recurrent Low Grade Ovarian Serous Adenocarcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Ovarian Clear Cell Adenocarcinoma;   Recurrent Ovarian Endometrioid Adenocarcinoma;   Recurrent Ovarian Mucinous Adenocarcinoma;   Recurrent Ovarian Transitional Cell  Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma Interventions:   Drug: Nedisertib;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride Sponsor:   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials